Results 151 to 160 of about 48,812 (228)

Durable benefits, but no improvements in overall survival: what can we learn from CheckMate 238 after 9 years of follow-up? [PDF]

Transl Cancer Res
Lopes CDH, Spreafico A, Araujo DV.
europepmc   +1 more source

Immune Checkpoint Inhibitor-Induced Vogt-Koyanagi-Harada-like Disease Complicated by Inflammatory Macular Neovascularisation: A Case Report and Literature Review. [PDF]

Diagnostics (Basel)
Papavasileiou ME, Stavrakas P, Mitri P, Kalaitzakis P, Makris G, Ragkousis A.   +5 more
europepmc   +1 more source

Rechallenge of ipilimumab and nivolumab in advanced melanoma patients after previous ipilimumab-based therapy: Clinical Studies

BACKGROUND: Ipilimumab+nivolumab (IPINIVO) can induce durable responses in advanced melanoma, but many patients experience progression at some point. It is currently unknown to what extent these patients benefit from IPINIVO rechallenge.
van der Veldt, A A M, van den Berkmortel, F W P J, MS Medische Oncologie, Hospers, G A P, Nienhuis, H H, Aarts, M J B, Vreugdenhil, G, van Dijk, E J, Blank, C U, Bloem, M, Bos, C, Kapiteijn, E, Wouters, M W J M, Piersma, D, Stevense-den Boer, A M, van den Eertwegh, A J M, de Groot, J W B, van Rijn, R S, Infection & Immunity, Pathologie Pathologen staf, Boers-Sonderen, M J, Suijkerbuijk, K P M, Blokx, W A M, Haanen, J B, Kamphuis, A M, Researchgr. Beeldg. Moleculaire Interv., Ros, M M, Cancer   +27 more
core  

Dual versus single-agent immune checkpoint inhibitor therapy in microsatellite instability-high metastatic colorectal cancer: an analysis based on reconstructed patient data. [PDF]

ESMO Gastrointest Oncol
Zaidi A, Vasconcelos JPS, Miranda TDA, Gill S, Raghav KPS, Loree JM.   +5 more
europepmc   +1 more source

Pharmacovigilance analysis of immune checkpoint inhibitor-associated optic nerve toxicity based on the FAERS database. [PDF]

Front Pharmacol
Bao H, Lin L, Huan W, Bao H, Su H, Luo X, Deng C, Hu J, Cao X, Wu X.   +9 more
europepmc   +1 more source

Immunotherapy Rechallenge in HCC: A Second Chance for Response? [PDF]

Liver Int
Da Fonseca LG, Guerrero A, Muñoz-Martínez SG.   +2 more
europepmc   +1 more source

Successful Combination Immunotherapy for Postoperative Recurrence of Esophageal Cancer Following Prior Immune Checkpoint Inhibitor Treatment: A Case Report. [PDF]

Surg Case Rep
Sakada R, Kawazoe T, Natsugoe K, Shin Y, Imoto Y, Harima T, Nambara S, Tsuda Y, Nakanoko T, Ando K, Oki E, Yoshizumi T.   +11 more
europepmc   +1 more source

Clinical characteristics, management, and prognosis of ipilimumab-induced hypophysitis: a retrospective analysis of 76 cases. [PDF]

Front Endocrinol (Lausanne)
Wu L, Yang Y, Su Q.
europepmc   +1 more source

Ipilimumab and nivolumab for cancer treatment: a pharmacovigilance study based on the FDA adverse event reporting system database. [PDF]

Front Endocrinol (Lausanne)
Liu R, Xiang Y, Hu X, Zhang M, Wang L, Liu T, Wang X, Qian B.   +7 more
europepmc   +1 more source

The toxicity profile and temporal dynamics of dual PD-1/CTLA-4 immune checkpoint blockade: a real-world pharmacovigilance study using the FAERS database. [PDF]

Front Immunol
Yang Y, Song S, Fan C, Luo Q, Wang C, Luo Y.   +5 more
europepmc   +1 more source